Industry Benchmarking Disclosure for Intangible Asset Amortisation Periods Pre-IPO

The Hong Kong Stock Exchange (HKEX) has intensified its scrutiny of intangible asset amortisation policies in listing applications, with a specific focus on whether the chosen periods reflect industry-specific benchmarks rather than generic corporate assumptions. This shift, observed across 2024 and into 2025, responds to a rising number of issuers—particularly in technology, healthcare, and consumer brands—adopting amortisation periods that diverge materially from those used by their publicly listed peers. The Exchange’s Listing Division now routinely issues substantive comments under HKEX Listing Rules Chapter 9 (for Main Board) and Chapter 14 (for GEM), requesting applicants to justify amortisation periods with reference to third-party industry data, competitor filings, or independent expert reports. For CFOs, company secretaries, and sponsor teams, the implication is direct: an inadequately supported amortisation policy can trigger multiple rounds of regulatory queries, delay the listing timetable, and, in extreme cases, lead to a rejection of the application. This article examines the regulatory framework, the mechanics of industry benchmarking disclosure, and the practical steps required to align an issuer’s intangible asset amortisation policy with HKEX expectations.

The Regulatory Framework for Amortisation Period Justification

HKEX does not prescribe a fixed amortisation period for intangible assets, but its guidance under Listing Decision HKEX-LD100-2019 and subsequent updates to the “Guidance for Listing Applicants” (2023 edition) establish a clear expectation: the period must reflect the asset’s expected useful life, supported by objective evidence. The Exchange’s review process examines whether the chosen period is consistent with industry practice, the issuer’s historical experience, and the asset’s projected economic benefits.

The Listing Division’s Documentary Requirements

When an applicant proposes an amortisation period that exceeds 10 years for software or 15 years for brand-related intangibles, the Listing Division typically requests a detailed breakdown. The required documentation includes:

• A comparison table showing amortisation periods adopted by at least five comparable listed companies in the same industry, sourced from their annual reports (HKEX Listing Rules Appendix 16, paragraph 27 requires disclosure of amortisation policies in the prospectus).
• An independent valuation report prepared under HKICPA’s Valuation Standards for Financial Reporting (2018 edition), confirming the economic life of the intangible asset.
• Historical data on the asset’s renewal or replacement cycle, if applicable. For example, a pharmaceutical company amortising a drug patent over 20 years must provide evidence of patent term extensions or market exclusivity data from the PRC National Medical Products Administration or equivalent overseas regulators.

The Listing Division has rejected applications where the issuer relied solely on management estimates without external benchmarking. In one 2024 case involving a PRC-based SaaS provider, the Exchange required the applicant to reduce its software amortisation period from 15 years to 8 years after comparing it with publicly listed peers such as Kingdee International Software Group (HKEX: 0268) and Yonyou Network Technology (Shenzhen: 600588), both of which use 5- to 10-year periods for similar assets.

The Role of Industry-Specific Standards

The Exchange’s approach varies by sector. For technology companies, HKEX expects amortisation periods to align with the rapid obsolescence cycles typical of software and platforms. The Listing Decision HKEX-LD100-2019 explicitly notes that for “technology-based intangible assets, a useful life exceeding 10 years is exceptional and requires compelling evidence.” In contrast, for regulated industries such as utilities or telecommunications, where intangible assets like licences or spectrum rights have legal durations of 15 to 30 years, longer amortisation periods are more readily accepted.

For healthcare and pharmaceutical issuers, the key benchmark is the patent life remaining at the time of listing, adjusted for regulatory approval timelines. The SFC’s Code on Share Buy-backs (2022 edition) indirectly reinforces this by requiring issuers to disclose the basis for amortisation in their financial statements, which must be consistent with the underlying asset’s legal protection.

Practical Mechanics of Industry Benchmarking Disclosure

Building a defensible amortisation policy requires more than citing a few competitor filings. The HKEX expects a structured, data-driven approach that addresses both the asset’s intrinsic characteristics and its market context.

Constructing the Benchmarking Universe

The first step is to select a comparator group that is truly comparable. The Listing Division has rejected benchmarks based on companies in different sub-sectors or geographies without adequate justification. For a PRC-based biotech firm amortising a monoclonal antibody patent, the comparator group should include:

• PRC-listed biotech companies on the Hong Kong Main Board (e.g., BeiGene Ltd. (HKEX: 06160) or Innovent Biologics (HKEX: 01801)).
• US-listed biotech firms with similar asset profiles, provided the issuer explains differences in regulatory environments (e.g., FDA vs. NMPA approval timelines).
• At least one Hong Kong-listed company in the same HKEX industry classification (e.g., “Biotechnology” under the Healthcare sector).

The disclosure in the prospectus must include a table showing each comparator’s amortisation period, the type of intangible asset, and the source document (e.g., “Annual Report 2024, Note 12”). The issuer should also explain any outliers. For example, if a comparator uses a 20-year period for a patent with 8 years remaining, the issuer must note that the period reflects the legal life rather than the economic life—a distinction that the Listing Division examines closely.

Handling Assets with Indefinite Lives

Some intangible assets, such as certain trademarks or broadcast licences, may be classified as having indefinite useful lives under HKAS 38 (Intangible Assets). The HKEX permits this classification only if the issuer can demonstrate that the asset’s economic benefits will continue for an indeterminable period with no foreseeable limit. The Listing Division requires:

• A legal opinion confirming the renewability of the licence or trademark registration.
• Historical evidence of uninterrupted renewals over at least 10 years.
• A sensitivity analysis showing the impact on profit if the asset were amortised over a 20-year period.

In a 2023 application by a Hong Kong-based media company, the Exchange rejected an indefinite-life classification for a television broadcast licence, requiring the issuer to amortise it over 15 years based on the licence’s renewal cycle under the Communications Authority’s regulatory framework.

Common Pitfalls and Remediation Strategies

Despite clear guidance, many applicants continue to face challenges. The most frequent issues include reliance on outdated industry data, failure to adjust for asset-specific factors, and inadequate disclosure of management assumptions.

The Problem of Stale Benchmarks

The Listing Division has flagged applications where the benchmarking data is more than 18 months old at the time of filing. Given the rapid pace of technological change, a 2022 amortisation period for a software asset may no longer be relevant in 2025. The issuer should update its comparator analysis within three months of the listing application date. If a key comparator has changed its amortisation policy in its most recent annual report, the issuer must reflect that change in its disclosure and explain whether it affects its own policy.

Sponsors should also verify that the comparator’s amortisation period is consistently applied across all similar assets. A company may use a 10-year period for one software product but a 5-year period for another, depending on the product’s life cycle. The Listing Division expects the issuer to explain such discrepancies in its own benchmarking analysis.

The Asset-Specific Adjustment Requirement

Generic industry averages are insufficient. The HKEX requires the issuer to adjust the benchmark for asset-specific factors:

• Legal protection: A patent with 12 years remaining should not be amortised over 20 years, even if the industry average is 20 years, unless the issuer has a clear path to patent extension (e.g., under the PRC Patent Law Article 42, which allows for patent term compensation).
• Market demand: A brand intangible for a product with declining sales should have a shorter amortisation period than the industry average. The issuer must provide revenue projections and market research data to support the chosen period.
• Technological obsolescence: For software assets, the issuer should reference the product’s expected upgrade cycle. If the issuer plans to release a new version every three years, the amortisation period should reflect that, not the 10-year period used by a competitor with a mature, stable platform.

The Disclosure of Management Assumptions

The prospectus must include a detailed note on the key assumptions underlying the amortisation period. Under HKAS 38.88, the issuer must disclose the carrying amount of intangible assets with indefinite useful lives, the reasons supporting the indefinite-life classification, and any changes in amortisation periods during the reporting period. The Listing Division has requested additional disclosure where the assumptions are not clearly linked to the benchmarking data. For example, if the issuer assumes a 5% annual revenue growth for a brand asset but the comparator group shows 2% growth, the issuer must explain the divergence and provide supporting evidence from independent market forecasts.

Actionable Takeaways for Listing Applicants

1. Build the benchmarking universe early: Identify at least five comparable listed companies in the same HKEX industry classification and sub-sector, and verify their amortisation periods from their most recent annual reports, updating the analysis within three months of the listing application date.

2. Adjust for asset-specific factors: Do not rely on industry averages alone; provide a written explanation for any deviation from the comparator group, referencing legal protection, market demand, or technological obsolescence data from independent sources.

3. Prepare for the Listing Division’s follow-up questions: Anticipate requests for sensitivity analyses (e.g., impact on profit if the amortisation period is reduced by 50%) and have independent valuation reports and legal opinions ready for assets with indefinite lives or periods exceeding 15 years.

4. Update the disclosure for material changes: If a comparator changes its amortisation policy between the initial filing and the hearing, amend the prospectus accordingly and explain the impact on the issuer’s own policy.

5. Engage the sponsor’s valuation team early: The independent valuation report required under HKICPA standards should be commissioned at least six months before the listing application to allow for iterative discussions with the Listing Division on the appropriateness of the amortisation period.